We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Pyxis Oncology Inc is a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. It develops the product candidates with the objective to directly kill tumor cells, and to address the ... Pyxis Oncology Inc is a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. It develops the product candidates with the objective to directly kill tumor cells, and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion. Show more
β PYX-201 achieved a confirmed 50% ORR by RECIST 1.1 including one Complete Response and 100% Disease Control Rate in six heavily pretreated HNSCC patients, supporting differentiated mono and...
- Preliminary data from the first-in-patient Phase 1 dose escalation trial of PYX-201 to be announced at upcoming virtual and in-person event in New York City on Wednesday, November 20, 2024, at...
BOSTON, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.1006 | 5.26867078663 | 1.9094 | 2.12 | 1.76 | 2222724 | 1.87595366 | CS |
4 | -1.74 | -46.4 | 3.75 | 5.3899 | 1.76 | 2195675 | 2.71020269 | CS |
12 | -1.48 | -42.4068767908 | 3.49 | 5.3899 | 1.76 | 1068756 | 3.011261 | CS |
26 | -1.81 | -47.3821989529 | 3.82 | 5.3899 | 1.76 | 806227 | 3.16169697 | CS |
52 | 0.39 | 24.0740740741 | 1.62 | 6.85 | 1.59 | 711524 | 3.72636371 | CS |
156 | -10.37 | -83.7641357027 | 12.38 | 12.61 | 1.1 | 640948 | 3.84855848 | CS |
260 | -16.99 | -89.4210526316 | 19 | 19 | 1.1 | 623325 | 4.03197364 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions